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AbstrACt
Objective To prospectively evaluate safety and efficacy of 
the ultrathin strut biodegradable polymer-coated Supraflex 
sirolimus-eluting stent (S-SES) in ‘real world’ patient 
population requiring percutaneous coronary intervention 
(PCI).
Methods National, prospective, multicentre, single-
arm, all-comers, observational registry of 469 patients 
treated with S-SES from July 2015 and November 2016 
in 11 centres in UK. Primary endpoint was target lesion 
failure (TLF) at 12 months (cardiac death, target vessel 
myocardial infarction (MI) or clinically driven target lesion 
revascularisation (TLR)). Secondary endpoints included 
safety and performance outcomes at 12 months—overall 
stent thrombosis (ST), all-cause mortality, any MI, target 
vessel failure (TVF) and major adverse cardiac events 
(MACE—composite of cardiac death, MI, emergent or 
repeat revascularisation).
results At 12 months, the primary endpoint occurred in 
11 (2.4%) of 466 patients, consisting of 4 (0.9%) cardiac 
deaths, 3 (0.6%) target vessel MI and 7 (1.5%) TLR. 
Secondary endpoints findings included all-cause mortality 
in 6 (1.3%), TVF of 14 (3%), no definite ST, 1 (0.2%) 
probable ST and 3 (0.6%) possible ST. Overall MACE was 
observed in 18 (3.9%).
Conclusions The S-FLEX UK registry showed that the 
S-SES is safe with a low incidence of TLF in routine clinical 
practise in patients with coronary artery disease being 
treated by PCI.
IntrOduCtIOn
Drug-eluting stents (DES) reduce neointimal 
proliferation and restenosis compared with 
bare-metal stents.1 2 However, the persistence 
of adverse events with both first-generation 
and contemporary permanent polymer-based 
DES presents an opportunity for iterative 
improvement.3–5 These include development 
of new metal alloys with thin struts, improved 
stent design and development of bioresorb-
able polymers.6–10
The potential link between durable 
polymer and late adverse events prompted 
development of biodegradable polymers to 
reduce inflammatory response, facilitating 
re-endothelialisation and minimising risk of 
thrombus formation and late restenosis.11 12 
Furthermore, first-generation DES with thick-
strut design, are associated with more throm-
botic events in ex vivo and experimental 
models.13 14 Newer DES technologies, with 
progressively thinner stent struts and biode-
gradable polymers promise additional benefit 
in terms of earlier re-endothelialisation and 
reduced restenosis.15 16
In this multicentre UK registry, the objec-
tive was to assess safety and outcomes at 12 
months of the CE-approved Supraflex (Saha-
janand Medical Technologies (SMT) Pvt Ltd, 
Surat, India), a biodegradable polymer-coated 
SES, ultrathin (60 µm) cobalt-chromium 
(Co-Cr) stent for the treatment of coronary 
artery disease (CAD) treated in routine clin-
ical practice.
strengths and limitations of this study
 ► The S-FLEX UK registry provides reassuring evidence 
that the ultrathin strut biodegradable polymer-coat-
ed sirolimus-eluting Supraflex stent can be safely 
and effectively used in routine clinical practice in UK 
patients with coronary artery disease being treated 
by percutaneous coronary intervention (PCI).
 ► The findings add to the emerging evidence that ul-
trathin strut biodegradable polymer stents can be 
used safely for PCI in routine clinical practice with 
the potential of further reducing target lesion failure.
 ► This is a non-randomised observational study of 
relatively small patient population with the inher-
ent limitations of such studies. Nevertheless, the 
findings are consistent with other studies using the 
same product.
 ► The follow-up period was 12 months, and a longer 
period of follow-up would allow for more accurate 
assessment of very late stent thrombosis.
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Figure 1 Bio-degradable polymer matrix of Supraflex 
sirolimus-eluting stent. Drug dose: 1.4 µg/mm2 · Unique 
biodegradable polymer matrix: poly L-lactide, 50/50 poly DL-
lactide-co-glycolide and polyvinyl pyrrolidone· Total coating 
thickness of 4–5 µm.
MethOds
study design and patient population
The S-FLEX UK registry was a prospective, observa-
tional, multicentre, postmarketing registry designed to 
evaluate the safety and efficacy of the Supraflex sirolim-
us-eluting stent (S-SES) in a ‘real-world’ patient popu-
lation. The study enrolled 469 patients from July 2015 
until November 2016 in 11 centres in UK. All patients 
over the age of 18, undergoing percutaneous coronary 
intervention (PCI) with at least one study stent, according 
to guidelines for revascularisation, irrespective of indi-
cation, disease location or complexity, were eligible for 
enrolment. In keeping with its real-world design, exclu-
sion criteria were minimal and included patients with 
a high-probability of non-adherence to the follow-up 
requirements (due to social, psychological or medical 
reasons); females of childbearing age; those with planned 
surgery within 6 months of PCI unless dual antiplatelet 
therapy (DAPT) could be maintained throughout the 
peri-surgical period; those participating in another study 
that has not completed the primary endpoint or that clin-
ically interfered with the current registry requirements 
and those with a known intolerance to aspirin, any P2Y12 
drug, heparin, bivalirudin, cobalt, chromium, sirolimus 
or any other analogue or derivative, or contrast media. 
The registry, design and procedures complied with the 
principles of good clinical practice and the Declaration of 
Helsinki and were approved by the local ethics committee 
of each participating institution.
Patient and public involvement: All patients provided 
informed consent for the procedure and subsequent data 
collection and analysis for the research purposes. Patient 
and public were not involved in the designing of the 
registry, recruitment or conducting the registry.
device description
The S-SES is a balloon-expandable stent using a medical 
grade cobalt-chromium alloy with ultra-thin struts of 
60 µm and crowns which are linked together by flexible 
‘S’ links to provide flexibility and improved deliverability. 
The coating layer, applied on the conformal surface of 
the stent with a mean thickness of 4–5 µm, comprises 
sirolimus, at a concentration of 1.4 µg/mm2, blended 
together with biodegradable polymeric matrix (poly 
L-lactide, 50/50 poly DL-lactide-co-glycolide and poly-
vinyl pyrrolidone). The polymer facilitates programmed 
release such that 70% of the drug is released within 7 
days and the remaining released over 48 days. The poly-
mers retain their properties for a limited period and 
then gradually degrade into biologically inert molecules 
and excreted via normal metabolic pathways over 9–12 
months. In addition, the device has a top protective layer 
that protects from light and moisture preventing prema-
ture drug release (figure 1). The device is available in 
diameters of 2.0, 2.25, 2.5, 2.75, 3.0, 3.50, 4.0 and 4.5 mm 
and in lengths increasing in 4 mm intervals from 8 to 
48 mm. Across the range, the strut thickness is 60 µm.
study procedure
Standard interventional techniques were used to treat the 
lesion, with predilatation and postdilatation, procedural 
anticoagulation, use of glycoprotein IIb/IIIa inhibitors 
and duration of DAPT left to the operator’s discretion.
data collection and follow-up
Patient demographic data, lesion characteristics, proce-
dure details and antithrombotic regimens were collected 
from each centre as per the prespecified case report form.
Follow-up was obtained at 12 months (±30 days) after 
the index procedure by hospital visit (14%) or telephonic 
follow-up. During follow-up consultations, information 
about patients’ clinical condition, adverse events, hospi-
talisations and changes to concomitant (cardiac and anti-
platelet) drugs were collected. Details of the above were 
further corroborated with review of the patients’ elec-
tronic records and/or contacting the general practitioner.
Angiographic data were recorded for patients read-
mitted with ischaemia. For patients readmitted for isch-
aemia who underwent angiographic re-examination 
within 1 year, image analysis was performed to determine 
whether disease progression had occurred at the previ-
ously stented segment, including peri-stent areas 2 mm 
adjacent to the stent, or was limited to arterial segments 
remote from the stented region. If repeat angiography 
was performed <30 days after successful stent place-
ment during the index procedure and demonstrated a 
significant stenosis or subacute stent thrombosis (ST) 
in the target vessel, the subject was considered an acute 
failure. If angiography took place >30 days after the index 
procedure and demonstrated restenosis of the target 
vessel and/or target lesion in association with objective 
evidence of recurrent ischaemia, the angiogram was anal-
ysed according to the secondary endpoints.
All events were investigator reported at site with no 
independent clinical events committee; however, site 
monitoring was performed to ensure continued protocol 
compliance and accurate data reporting by Psephos 
Biomedica (Sussex Innovation Centre, University of 
Sussex, Brighton BN1 9 SB, UK).
study endpoints
The primary endpoint of the study was target lesion failure 
(TLF) at 12 months: a composite of cardiac death, target 
vessel myocardial infarction (MI) or clinically driven 
target lesion revascularisation (TLR) by percutaneous 
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Table 1 Baseline characteristics of the study population
n (%) unless stated
Patient characteristics n=466
Age, mean±SD (years) 64.8±10.4
Male 350 (75.1%)
Body mass index (kg/m2) 28.9±6.1
Diabetes mellitus 113 (24.2%)
  Insulin requiring 30 (6.2%)
  Non-insulin requiring 83 (18.0%)
Hypertension 237 (50.9%)
Hypercholesterolemia 251 (53.9%)
Family history of CAD 226 (48.5%)
Current smoker 120 (25.8%)
Renal insufficiency 10 (2.1%)
Peripheral vascular disease 17 (3.6%)
Congestive heart failure 12 (2.6%)
Previous transient ischaemic attack 12 (2.6%)
Previous stroke 17 (3.6%)
Previous myocardial infarction 127 (27.3%)
Previous PCI 108 (23.2%)
Previous CABG 18 (3.9%)
Acute coronary syndromes 278 (59.7%)
  Unstable angina 187 (40.2%)
  Silent ischaemia 10 (2.1%)
  NSTEMI 58 (12.5%)
  STEMI 23 (4.9%)
Stable angina 188 (40.3%)
Lesion characteristics n=573 lesions
Number of lesions per patient 
(mean±SD)*
1.23 (±0.5)
Target vessel   
  Left main stem 7 (1.2%)
  Left anterior descending 249 (43.5%)
  Left circumflex 119 (20.8%)
  Right coronary artery 197 (34.4%)
  Saphenous vein graft 1 (0.2%)
Re-stenotic lesion 16 (2.8%)
Bifurcation 61 (10.6%)
Total occlusion 75 (13.1%)
CABG, coronary artery bypass grafting; CAD, coronary artery 
disease; NSTEMI, non ST elevation myocardial infarction; 
PCI, percutaneous coronary intervention; STEMI, ST-elevation 
myocardial infarction.
or surgical methods. Secondary endpoints assessed at 
12 months included: overall ST; any death; any MI; any 
repeat revascularisation; target vessel failure (TVF) (a 
composite of cardiac death, target vessel MI or clinically 
driven TVR) and major adverse cardiac events (MACE—a 
composite of cardiac death, any MI, emergent or repeat 
revascularisation).
statistical analysis
The sample size of subjects was selected to be similar to 
the patient numbers enrolled in the S-CORE registry.17 
Data are presented using descriptive statistical methods. 
Continuous variables are presented as mean±SD, whereas 
categorical variables are expressed as percentages. All 
data were processed using the SPSS V.15
results
baseline, lesion and patient characteristics
The S-FLEX registry enrolled 469 patients from 11 centres 
in UK between the prespecified recruitment periods of 
July 2015 to November 2016. Three patients withdrew 
consent and 12 were lost to follow-up leaving 454 (97.4%) 
patients for 12 months’ clinical follow-up.
Baseline patient, lesion and procedural characteristics 
are shown in tables 1 and 2. Consistent with the all-comers 
design and reflective of a high-risk population active 
smoking, presence of diabetes, medical history of MI and 
revascularisation was noted in a quarter while over half 
had hypertension and hyperlipidaemia. Not all partici-
pating centres had a primary angioplasty service thereby 
explaining the lower number of patients with ST-eleva-
tion myocardial infarction that were recruited. However, 
in line with contemporary UK practice, the main indica-
tion for revascularisation was acute coronary syndrome 
(59.7%).18 The mean number of lesions per patient 
was 1.23±0.5, with >10% of these lesions bifurcations or 
chronic total occlusions. The mean number of stents 
deployed per patient was 1.48±1.0, with average length 
of coronary artery stented was 32.99±24.70 mm. Overall 
device implantation success on the lesion was 98.6%.
Clinical outcomes
Patient outcomes at 30 day, 6 months and 12 months are 
shown in table 3. The rate of the primary endpoint of 
TLF was 2 (0.4%) and 8 (1.7%) at 30 days and 6 months, 
respectively. At 12 months, the components of TLF, 
cardiac death was observed in 4 (0.9%), target vessel MI 
in 3 (0.6%) and TLR in 7 (1.5%). Cumulative TLF-free 
survival, at 12 months’ follow-up, determined by the 
Kaplan-Meier method, was 97.4% as shown in figure 2.
Secondary endpoints findings included all-cause 
mortality in 6 (1.3%) and TVF in 14 (3%). According 
to ARC definition, overall ST was observed in 4 (0.8%) 
including no definite ST, 1 (0.2%) probable ST and 3 
(0.6%) possible ST. Overall MACE were observed in 18 
(3.9%) patients.
dIsCussIOn
This UK multicentre real-world registry of the thin strut, 
cobalt-chromium, biodegradable polymer S-SES demon-
strated safety with a low incidence of TLF and ST at 12 
months.
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Table 2 Procedural characteristics
Mean±SD unless stated
Procedural characteristics n=691 stents
No. of stents per patient 1.48±1.0
No. of stents per lesion 1.21±0.5
Mean stent length 22.48±7.6
Mean stent diameter 3.01±0.4
Predilatation, n (%) 471 (82.2)
Postdilatation, n (%) 394 (68.8)
Total stent length per patient 32.99±24.70
Device success (%) 98.6
Table 3 Hierarchical and non-hierarchical subject counts of adverse events through 12 months (intent-to-treat population)
n (%) 30 days 6 months 12 months
Hierarchical events
TLF 2 (0.4) 8 (1.7) 11 (2.4)
  Cardiac death 1 (0.2) 3 (0.6) 4 (0.9)
  Target-vessel MI 1 (0.2) 3 (0.6) 3 (0.6)
  Target-lesion revascularisation 0 (0) 5 (1.1) 7 (1.5)
  Target vessel failure 2 (0.4) 11 (2.4) 14 (3.0)
  Major adverse cardiovascular events 4 (0.9) 14 (3.0) 18 (3.9)
Non-hierarchical events
Death 1 (0.2) 1 (0.2) 6 (1.3)
  Cardiac death 1 (0.2) 3 (0.6) 4 (0.9)
  Non-cardiac death 0 (0.0) 1 (0.2) 2 (0.4)
Myocardial infarction
Target vessel 1 (0.2) 3 (0.6) 3 (0.6)
Non-target vessel 2 (0.4) 3 (0.6) 4 (0.9)
Revascularisation
  Target lesion revascularisation 1 (0.2) 5 (1.1) 7 (1.5)
  Target vessel revascularisation 1 (0.2) 10 (2.2) 14 (3.0)
Non target vessel revascularisation 2 (0.4) 4 (0.8) 6 (1.2)
  Stent thrombosis 1 (0.2) 3 (0.6) 4 (0.9)
  Definite ST 0 (0.0) 0 (0.0) 0 (0.0)
  Probable ST 1 (0.2) 1 (0.2) 1 (0.2)
  Possible ST 0 (0.0) 2 (0.4) 3 (0.6)
MACE, major adverse cardiac events (composite of cardiac death, any MI, emergent or repeat revascularisation); MI, myocardial Infarction; 
ST, stent thrombosis; TLF, target lesion failure (composite of cardiac death, target vessel MI or clinically driven TLR); TVF, target vessel failure 
(composite of cardiac death, target vessel MI and TVR); TVR, target vessel revascularisation.
Figure 2 Kaplan-Meier curve of target lesion failure.
Concerns related to impaired healing and persistent 
inflammation associated with first-generation durable 
polymer DES, led to the development of improved 
polymers, metallic platform technologies and thinner 
struts.3–10 14 The change in stent platform from stainless 
steel (132–140 µm) to chromium alloys (81–91 µm), 
reduced both procedural and late target vessel MI by 
about 40%–80%.19–22 The BIOFLOW V study compared 
the ultrathin strut (60 µm) bioresorbable polymer 
sirolimus-eluting Orsiro stent with the thin strut (81 µm) 
durable polymer everolimus-eluting Xience stent and 
reported an approximate further 40% reduction in target 
vessel MI in favour of Orsiro10 The Orsiro stent polymer 
degrades over a 2 year span and thus the observed outcome 
differences at 1 year between the Orsiro and Xience stents 
are possibly largely driven by the difference in strut thick-
ness rather polymer durability. Pooled analysis of large 
multicentre randomised trials reported lower risk of TVR 
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Figure 3 12-Month target lesion revascularisation and target lesion failure of contemporary stents.1–6 See references.10 22 37–40
and very late ST associated with biodegradable polymers 
compared with durable polymer-coated DES.23 However, 
it remains debatable whether this reduction of adverse 
events is a class effect of biodegradable polymers and may 
well be influenced by additional factors including stent 
strut thickness, polymer composition, distribution and 
load.24 25
Studies assessing the Supralimus-Core (previous version 
of the S-SES with the same strut thickness, polymer 
and drug concentration) reported reassuring vessel 
healing properties by optical coherence tomography at 
4 months,26 along with satisfactory 1-year TLR of 1.1% 
along with MACE of 3.4% in real-world patients.17
The S-SES is an improved version of the Supralim-
us-Core SES with replacement of the rigid interlink/joint 
of the Supralimus-Core SES with a highly flexible ‘S-link’, 
which increases flexibility and deliverability. Preliminary 
evaluation of clinical and angiographic outcomes of the 
Supraflex stent in the MANIPAL-FLEX Study reported a 
TLR of 2.1%.27 Angiographic in-stent late lumen loss, a 
dependable predictor of the long-term clinical efficacy of 
DES,28 was observed to be 0.18±0.23 mm with the Supra-
flex stent at 9 months in keeping with currently used 
effective DES systems.29–31
The subsequent retrospective, multicentre FLEX 
registry that included 995 unselected patients treated 
with the S-SES across nine centres in India reported a 
12-month MACE of 3.7%.32 This included TLR of 0.7%, 
definitive ST of 0.3% and overall ST of 1.1% at 12 months. 
Late ST remains a major concern even in contemporary 
DES and has been shown to be dependent on lack of strut 
coverage.33 In the FLEX registry OCT subgroup analysis, 
the authors reported 98.1% strut coverage at 6 months 
with the S-SES, that compared favourably with the 
91.5% and 94.1% strut coverage reported with Promus 
Element and Xience DES.34 The authors also reported 
S-SES to have an excellent healing index of 4.8 (1.0–
22.9) comparing favourably with BioMatrix (35.2±25.0), 
Cypher (43.3±36.2), Resolute (18.7±20.4) and the Xience 
(10.8±15.3) DES systems.35 36
In this registry, 12-month TLF of 2.4% and TLR of 1.5% 
is in keeping with the previous findings of the S-SES in 
the MANIPAL-FLEX and FLEX registries. These findings 
are encouraging when compared with the 12-month TLR 
and TLF of contemporary DES systems (figure 3).10 22 37–40 
The promising clinical outcomes with the S-SES might be 
attributed to the combination of its ultrathin struts, biode-
gradable polymer and unique platform design. Extensive 
strut coverage within 4–6 months and low ‘healing index’ 
provide possible explanations for low ST and TLR rates.41 
The relative safety and efficacy of the S-SES seen in this 
registry was confirmed by the TALENT (Thin strut siroli-
mus-eluting stent in All comers’ population vs Evorolim-
us-eluting stent) study.
study limitations
This was a non-randomised observational study of rela-
tively small patient population with the inherent limita-
tions of such studies. Nevertheless, the findings were 
consistent with other studies using the same product and 
complications at 12 months were qualitatively similar to 
contemporary DES. The end points were not adjudicated 
by a core laboratory, but all events reported were verified 
by external, qualified clinical trial monitors. No ECG was 
performed as part of the 12-month FU and majority of 
the follow-up was via telephonic questionnaire raising the 
possibility of under-reporting of endpoints. However, the 
study endpoints were ‘clinically driven’ and every effort 
was made to capture clinical events by reviewing the 
patients’ electronic health records in addition to the in 
person/telephonic follow-up.
COnClusIOns
The S-FLEX UK registry provides evidence that the S-SES 
can be used safely and effectively in routine clinical prac-
tice in UK patients with CAD being treated by PCI.
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